Exagen
Venture Round in 2019
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
TriSalus Life Sciences
Series C in 2015
TriSalus Life Sciences, based in Westminster, Colorado, focuses on developing innovative drug delivery technologies and immune-oncology therapeutics aimed at improving treatment outcomes for challenging cancers, particularly liver and pancreatic cancer. Founded in 2009, the company specializes in precision infusion systems designed for interventional radiology. Its product offerings include Pressure Enabled Drug Delivery (PEDD) systems, which utilize a unique expandable tip catheter to deliver embolic agents while minimizing damage to healthy tissues. The Surefire infusion systems, including various models for lobar, segmental, and super-selective infusions, aim to enhance tumor uptake through controlled pressure and blood flow management. Additionally, TriSalus is advancing an investigational therapy, nelitolimod, which has shown promise in enhancing immune response against liver tumors. The company continues to innovate with devices like the TriNav, which employs SmartValve technology to optimize drug delivery.
CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.
OrthoSensor
Series C in 2015
OrthoSensor, Inc. is a medical device company based in Dania Beach, Florida, focused on developing orthopedic devices that incorporate advanced sensor technology. The company's flagship product, VERASENSE, is a disposable instrument designed for total knee arthroplasty, providing real-time evidence-based data to surgeons during surgery to aid in soft tissue balancing and implant positioning. Additionally, OrthoSensor offers OrthoLogIQ, a cloud-based data collection system that integrates data from the VERASENSE device with patient demographics and outcomes. The company aims to enhance patient outcomes and reduce treatment costs for musculoskeletal diseases through its innovative products and services. Founded in 2007, OrthoSensor also engages in training and education, as well as clinical and bioengineering research, and markets its solutions through a network of sales representatives across the United States.
CareSync is a prominent provider of software and services focused on chronic disease management. The company integrates technology with round-the-clock nursing services to enhance care coordination among patients, families, caregivers, and healthcare providers. CareSync offers comprehensive Chronic Care Management services, along with a software-only option, enabling healthcare practices of any size to comply with billing requirements for chronic care codes. Its certified technology also helps providers achieve Meaningful Use 2 standards for data exchange and timely access to health information. By centralizing records from various providers, CareSync allows for the secure storage and organization of health information, making it easily accessible for caregivers and healthcare professionals. This patient-centered approach empowers individuals with access to their health information and actionable goals, leading to more effective medical appointments and improved health outcomes.
Exagen
Debt Financing in 2014
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Exagen
Debt Financing in 2013
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Estech
Venture Round in 2012
Estech is a privately held medical device manufacturing and distribution company based in San Ramon, California. Founded in 1996 by Arthur and Raymond Bertolero, the company focuses on developing and marketing medical devices and disposables that facilitate both traditional and minimally invasive cardiac surgical procedures. Estech has established a global distribution network and is recognized for attracting skilled professionals in the medical device sector. The company's commitment to innovation and quality has enabled it to achieve sustained success in a competitive industry, reflecting the dedication of its team across all departments.
Exagen
Venture Round in 2012
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Exagen
Venture Round in 2011
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Exagen
Venture Round in 2011
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Exagen
Venture Round in 2011
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Estech is a privately held medical device manufacturing and distribution company based in San Ramon, California. Founded in 1996 by Arthur and Raymond Bertolero, the company focuses on developing and marketing medical devices and disposables that facilitate both traditional and minimally invasive cardiac surgical procedures. Estech has established a global distribution network and is recognized for attracting skilled professionals in the medical device sector. The company's commitment to innovation and quality has enabled it to achieve sustained success in a competitive industry, reflecting the dedication of its team across all departments.
BioBehavioral Diagnostics
Series B in 2010
BioBehavioral Diagnostics specializes in manufacturing diagnostic systems aimed at the quantitative assessment of behavioral and neurobiological disorders. The company is known for its Quotient ADHD System, which provides an objective and accurate evaluation of ADHD symptoms. Through its proprietary platform technology, BioBehavioral Diagnostics measures specific behaviors linked to brain function and inhibitory control deficits, collecting data on an individual's ability to remain still, manage impulsivity, and respond accurately to visual stimuli on a computer screen. The company is committed to delivering valuable information to physicians, parents, and patients, facilitating personalized strategies to improve the quality of life for those affected by ADHD.
Synageva BioPharma
Series F in 2009
Synageva BioPharma is a biopharmaceutical company that specializes in the development and commercialization of innovative protein therapeutics, particularly targeting rare diseases. Utilizing its proprietary Synageva Expression Platform, the company aims to create next-generation and follow-on therapies that address unmet medical needs. By focusing on rare diseases, Synageva seeks to improve treatment options and outcomes for patients with these conditions, thereby positioning itself as a key player in the biopharmaceutical sector.
Coherex Medical
Series B in 2009
Coherex Medical, Inc. specializes in the design, development, and marketing of catheter-based technologies aimed at treating structural heart defects. The company focuses on developing devices for patients with atrial fibrillation who are at risk for stroke, including an innovative closure system for the left atrial appendage (LAA) and a patent foramen ovale (PFO) closure system that promotes tissue in-growth for long-term closure. Founded in 2003 as Proximare, Inc., the company rebranded to Coherex Medical in 2006 and is headquartered in Salt Lake City, Utah. Coherex Medical serves both domestic and international markets, providing crucial treatment options for structural heart conditions. As of 2015, the company operates as a subsidiary of Biosense Webster, Inc.
VidaCare
Venture Round in 2009
Vidacare Corporation is a medical device company based in San Antonio, Texas, specializing in intraosseous access devices designed for use in diagnostic, monitoring, and therapeutic applications. The company’s flagship product, the EZ-IO Product System, enables controlled vascular access through the intraosseous route, particularly beneficial in emergency situations where traditional vascular access methods are ineffective. The EZ-IO power driver is engineered to penetrate the intraosseous space using a hollow needle and integrated stylet, ensuring accurate placement. Additionally, the EZ-IO Vascular Access Pack equips emergency medical personnel with the necessary tools to establish vascular access quickly. Vidacare also offers a range of hematology and oncology products, including systems for bone marrow aspiration and biopsy. Its innovations are utilized in various settings, including pre-hospital care, emergency response, and military operations, catering to the needs of healthcare providers in critical situations. Founded in 2001, Vidacare continues to advance intraosseous access technology for the medical community.
Synageva BioPharma
Series F in 2009
Synageva BioPharma is a biopharmaceutical company that specializes in the development and commercialization of innovative protein therapeutics, particularly targeting rare diseases. Utilizing its proprietary Synageva Expression Platform, the company aims to create next-generation and follow-on therapies that address unmet medical needs. By focusing on rare diseases, Synageva seeks to improve treatment options and outcomes for patients with these conditions, thereby positioning itself as a key player in the biopharmaceutical sector.
Intranasal Therapeutics
Series B in 2009
Ikano Therapeutics a specialty pharmaceutical company, focuses on developing nasal spray drug products.
Atritech
Venture Round in 2009
Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.
Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.
Atritech is a Minneapolis-based private company founded in 2000, specializing in innovative medical technologies aimed at preventing strokes related to atrial fibrillation. The company's flagship product, the WATCHMAN Device, offers a minimally invasive solution for patients with non-valvular atrial fibrillation at risk of stroke by sealing off the left atrial appendage, thereby preventing blood clots from entering the bloodstream. The WATCHMAN Device was first implanted in Germany in 2002 and in the United States in 2003, and has since undergone extensive clinical trials to compare its efficacy against traditional long-term anticoagulation therapies. While the device is CE marked and available in several international markets, it is currently classified for investigational use only within the United States. Atritech's technology aims to enhance the quality of life for patients by providing a permanent alternative to anticoagulant medications.
Aldagen is a biopharmaceutical company focused on developing proprietary regenerative cell therapies to address significant unmet medical needs. The company has four product candidates currently in clinical trials. The most advanced candidate, ALD-101, is undergoing a pivotal Phase 3 clinical trial to assess its efficacy in enhancing umbilical cord blood transplants for pediatric patients with inherited metabolic diseases. In addition, Aldagen is conducting or supporting Phase 1 or Phase 1/2 clinical trials for three other candidates: ALD-151, aimed at improving cord blood transplants for leukemia treatment; ALD-301, designed to address critical limb ischemia; and ALD-201, which targets ischemic heart failure.
Impulse Monitoring
Series A in 2007
Impulse Monitoring specializes in intra-operative neurophysiological monitoring solutions for hospitals and healthcare facilities, enhancing surgical safety during spinal, nerve, and brain surgeries. The company's IONM service provides critical insights into a patient's nervous system, alerting surgeons to potential risks and enabling informed decision-making. This technology is applicable across various surgical fields, including neurosurgery, orthopedic surgery, vascular surgery, cardiac surgery, and otolaryngology. By delivering real-time data on the condition of neural structures, Impulse Monitoring aims to reduce surgical risks and improve patient outcomes. The company is based in Columbia, Maryland.
BioBehavioral Diagnostics
Series A in 2007
BioBehavioral Diagnostics specializes in manufacturing diagnostic systems aimed at the quantitative assessment of behavioral and neurobiological disorders. The company is known for its Quotient ADHD System, which provides an objective and accurate evaluation of ADHD symptoms. Through its proprietary platform technology, BioBehavioral Diagnostics measures specific behaviors linked to brain function and inhibitory control deficits, collecting data on an individual's ability to remain still, manage impulsivity, and respond accurately to visual stimuli on a computer screen. The company is committed to delivering valuable information to physicians, parents, and patients, facilitating personalized strategies to improve the quality of life for those affected by ADHD.
Adiana, Inc. is a medical device company based in Redwood City, California, that specializes in the development of permanent contraceptive solutions for women. Founded in 1997, the company focuses on transcervical sterilization systems designed to prevent pregnancy by occluding the fallopian tubes. Its flagship product, Complete TCS, includes a radiofrequency generator, a delivery catheter, and an implantable matrix. This innovative approach offers a non-incisional alternative to traditional tubal ligation, allowing women to avoid the potential side effects and complications associated with other contraceptive methods. As of 2007, Adiana operates as a subsidiary of CYTYC Corp.
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Myocor is a medical company based in Minnesota that specializes in developing and distributing therapeutic devices aimed at treating mitral valve insufficiency and congestive heart failure. Founded in 1996, Myocor focuses on innovations that enhance cardiac function and improve clinical outcomes for patients with late-stage heart failure. One of its key products, Coapsys, employs a system of pads and a tensioned string inserted through the heart to reshape an enlarged heart and optimize the performance of a leaky mitral valve. Through its technologies, Myocor aims to address the challenges associated with heart failure and provide effective treatment options for affected individuals.
Valeo Medical
Series B in 2004
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
Transmolecular
Series C in 2004
TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.
Exagen Inc. is a diagnostics company focused on improving the care of patients with autoimmune diseases through the development and commercialization of innovative testing products under its AVISE brand. Utilizing its proprietary Cell-Bound Complement Activation Products technology, Exagen offers a range of tests aimed at the diagnosis, prognosis, and monitoring of complex autoimmune and autoimmune-related disorders, such as systemic lupus erythematosus and rheumatoid arthritis. Among its key products are AVISE CTD, which supports differential diagnosis for connective tissue diseases, and AVISE Lupus, which assesses complement system activation. The company's portfolio also includes AVISE APS for antiphospholipid syndrome, AVISE SLE Prognostic for risk assessment of complications, and tests for monitoring treatment efficacy in rheumatoid arthritis. Established in 2002 and headquartered in Vista, California, Exagen is dedicated to providing rheumatologists with timely and accurate diagnostic tools to enhance patient care.
Valeo Medical
Series A in 2003
Valeo Medical, Inc., a life sciences company, develops a non-invasive diagnostic blood test for endometriosis. The company was founded in 2003 and is based in Burlington, Massachusetts. Valeo raised money as part of the Discovery Life Sciences fund which was partly funded by the Nashville Capital Network.
BioRexis has developed proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability. This new platform supports Pfizer’s commitment to develop novel protein therapeutic agents.
Transmolecular
Series B in 2000
TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.
SupplyPro
Venture Round in 2000
SupplyPro, Inc. specializes in manufacturing and marketing inventory management solutions aimed at enhancing productivity and efficiency in various industries. The company's offerings include a range of systems such as SupplyAgent for basic material control, SupplyBay designed for harsh industrial settings, and SupplyLocker for managing tools and supplies. Additionally, SupplyLock enables electronic control of cabinets, while SupplyPad provides mobile inventory management for barcoded items. SupplySystem is a modular control system for indirect materials, accompanied by advanced software for intelligent inventory management. Their innovative solutions, including SupplyPro Virtual Inventory Management and SupplyScale, facilitate tracking and management of inventory transactions, even for items not physically present. SupplyPro's products cater to diverse sectors such as automotive, aerospace, energy, and food and beverage, and are used in applications ranging from manufacturing to maintenance. Founded in 1997 and based in San Diego, California, SupplyPro aims to streamline inventory processes while reducing costs and preventing stock-outs.
AmericasDoctor.com
Venture Round in 2000
AmericasDoctor, a unique pharmaceutical services company, combines and integrates leading physician researchers, strategic marketing and consumer outreach capabilities, distinguished hospitals and advanced Internet resources to assist the pharmaceutical industry in developing, positioning and promoting its products. AmericasDoctor was formed in January 2000 from a merger between Affiliated Research Centers (ARC) and AmericasDoctor.com. AmericasDoctor Research Services (formerly ARC) provides investigative site and patient recruitment capabilities through its 150 investigative sites operating in 37 states in the U.S. and five provinces in Canada. Currently, AmericasDoctor is conducting over 550 studies in urology, rheumatology, pulmonology and respiratory disease, endocrinology, cardiology, women’s health, gastroenterology and neuroscience. AmericasDoctor Web Services provides information to consumers in response to health information inquiries. It is the only medical/health Internet site to offer private, real-time, one-on-one chats with board-certified, board-eligible physicians 24 hours a day, seven days a week at no cost to the consumer. This site is sponsored by over 100 leading U.S. hospitals. AmericasDoctor supports the combined efforts of the medical community and pharmaceutical industry to improve the lives of people suffering from chronic illnesses. AmericasDoctor provides the vital link between the patient, the medical expert and the development of new therapies. To the consumer, this means enhanced lives, the empowerment to manage their medical situations and the possibility of improved treatment efficacy. For pharmaceutical companies, this means unique approaches in defining, developing and expediting new products and solutions. AmericasDoctor is a privately held company with a strategic vision to provide a new generation of pharmaceutical services integrating information, marketing and research resources to help create tomorrow’s medicine.
Centromine
Venture Round in 1999
Centromine offers a browser-based, internet-accessed, enterprise-wide software applications and services for the health care market. Its applications allow behavioral health care programs and providers to manage the delivery and associated quality and cost of services completely over the internet.
Transmolecular
Series A in 1997
TransMolecular, Inc. is a neuroscience biotechnology firm focused on discovering and developing innovative drugs for diagnosing and treating central nervous system diseases, particularly cancer and pain, where current treatment options are limited. Founded in 1996 and based in Birmingham, Alabama, the company has established robust technology platforms that support its product discovery and development efforts. It has received significant funding, including $9.6 million from venture capital sources and $1 million in Small Business Incentive Research grants from the National Institutes of Health. TransMolecular possesses over 25 patents and patent applications to safeguard its intellectual property and has exclusive licensing agreements with the University of Alabama at Birmingham Research Foundation and Yale University for its specialized technologies. The management team brings more than 75 years of combined experience in healthcare, pharmaceutical development, and related fields, underscoring the company’s commitment to creating safe and effective treatments for patients suffering from serious medical conditions.